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1 Postal address: Post Box Number 23, General Post Ofﬁce (GPO), Srinagar, Jammu and Kashmir 190001, India.Maniah Qadir, MS; Andleeb Ahangar, MS ⇑,1; Mohamed Ahsan Dar, MS; Sumaya Hamid, MS; Manzoor Qadir Keng, MSAbstractAims and objectives: To compare the outcome of dacryocystorhinostomy surgery with and without the intraoperative use of Mito-
mycin C.
Methods: Our study is a prospective comparative case study in which 50 patients of primary acquired nasolacrimal duct obstruc-
tion were divided on the basis of random sampling into the conventional dacryocystorhinostomy group and the Mitomycin C
group in which Mitomycin C 0.2 mg/ml was used intraoperatively. Patients were followed on 1st postoperative day, 1st, 3rd,
6th weeks, 3rd and 6th months. Patient symptoms and satisfaction were noted. Patency of lacrimal passage was assessed by lac-
rimal syringing and tear meniscus height was recorded on each follow-up.
Results: At the end of 6 months of follow-up, 96% of patients were asymptomatic in the Mitomycin C group whereas 80% patients
in the conventional group were asymptomatic. On lacrimal syringing 24 (96%) eyes had patent passage in the Mitomycin C group
where as only 1 (4%) patient had complete block with regurgitation of mucopurulent fluid. In the conventional group 20 (80%) eyes
had patent passage, 4 (16%) eyes had complete block with regurgitation of mucopurulent fluid and 1 (4%) eye had partially patent
passage on lacrimal syringing. Out of 25 eyes, 24 had normal tear meniscus height, and 1 had high tear meniscus height in the
Mitomycin C group in comparison to the conventional group in which out of 25 eyes 20 eyes had normal, 1 had moderate and
4 eyes had high tear meniscus height. Intraoperative and postoperative complications in both the groups were identical.
Conclusion: Although the difference between the two groups was not statistically significant, a distinctly higher success was
achieved in patients undergoing dacryocystorhinostomy with intra operative Mitomycin C as compared to conventional
dacryocystorhinostomy.
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Epiphora and discharge secondary to nasolacrimal duct
obstruction are common and troublesome problems among
patients presenting to an ophthalmologist. Primary acquired
nasolacrimal duct obstruction is believed to occur secondary
to a chronic inflammatory process resulting in fibrosis and
obliteration of the duct. Dacrocystorhinostomy is a widely ac-
cepted treatment for nasolacrimal duct obstruction wherebythe occluded duct is bypassed by creating an alternative
drainage route between the lacrimal sac and the nasal cavity
through a bony ostium. This is most often performed through
a skin incision which permits the creation of an epithelium
lined tract. However failure to maintain the patency of this
alternative drainage route results in the failure of this proce-
dure. A failure rate of 11–28% with an average of 9.4% has
been reported which necessitates improving the above tech-
nique.1 The two main causes of dacrocystorhinostomy failuree:
al.com
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osteotomy site by fibrosis and scar formation. Thus by inhib-
iting fibrous growth and subsequent scarring of the oteoto-
my site by using anti-proliferative agents over the
anastamosed flaps and osteotomy site, the failure rate may
be decreased.1 Mitomycin C is an antibiotic alkylating agent
which inhibits fibroblast proliferation and alters wound heal-
ing response leading to less fibrosis and scarring around
the common canaliculus and osteotomy site.1,2 In this paper
we evaluate the effectiveness of intra operative use of mito-
mycin C as an adjuvant during dacryocystorhinostomy to pre-
vent post operative fibrosis and scarring and hence decrease
in the failure rate.Materials and methods
This study was conducted in the postgraduate department
of ophthalmology, Government Medical College Srinagar on
50 patients of primary acquired nasolacrimal duct obstruc-
tion. This study was approved by the ethics committee and
informed consent was taken from each patient prior to sur-
gery. Exclusion criteria included pre-saccal obstructions,
acute dacryocystitis, chronic granulomatous condition, long
standing chronic dacryocystitis with fibrosis of sac, chronic
dacryocystitis with fistula, ectropion, entropion, nasal condi-
tions like severe deviated nasal septum, atrophic rhinitis,
and previous failure of dacrocystorhinostomy. On the basis
of simple random sampling these patients were divided into
two groups of 25 patients each. 25 cases underwent dacryo-
cystorhinostomy without Mitomycin C and 25 patients of dac-
ryocystorhinostomy with intraoperative application of
Mitomycin C.
Patients were followed up for a minimum of 6 months for
evaluation of subjective symptoms and objective findings.
Patients were followed postoperatively on 1st day, 1st, 3rd,
6th weeks, 3rd and 6th months.
Same technique of external dacryocystorhinostomy was
used in patients of both groups. 5 ml of lignocaine 2% with
adrenaline 1:200,000 was infiltrated around the lacrimal sac
for anesthesia and hemostasis. After anaesthetizing the nasal
mucosa by topical 4% xylocaine, packing of ipsilateral nasal
cavity was done with roller gauze soaked in 5 ml of 4% xylo-
caine with adrenaline 1:200,000. A curvilinear incision of
20 mm in length was made along the anterior lacrimal crest
starting 3 mm above the level of medial palpable ligament
and 3 mm medial to the medial canthus. After separating
the orbicularis muscle fibers, the medial canthal ligament
was divided and the lacrimal sac was separated from the fos-
sa by blunt dissection. The periostium was elevated off and
the lamina papyracea was fractured. An osteotomy of
approximately 10  10 mm in size was created. Lacrimal sac
and nasal mucosa were opened in a H fashion to form a large
anterior and a small posterior flap. The posterior flap was
then excised.
In the Mitomycin C group a piece of merocel surgical
sponge soaked in 0.2 mg/ml of Mitomycin C was applied
over osteotomy margins, undersurface of anterior flaps for
5 min. The lacrimal sac and nasal mucosal flaps were than su-
tured with 6/0 vicryl. Sponge was removed and normal saline
irrigated through the lower punctum and over the osteotomy
site. The two ends of medial palpebral ligament and incision
in the orbicularis were closed with 6/0 vicryl interruptedsutures. Skin incision was closed with 6/0 vicryl subcuticular
suture or interrupted sutures. Nasal pack was placed which
was removed after 24 h. Postoperatively patients received
systemic antibiotics and anti inflammatory drugs for 7 days
.Antibiotic eye drops were advised 6 times a day for 7 days.
To evaluate the results in both groups, both symptoms
and objective findings were recorded on follow up. Patient
symptoms were noted and classified as asymptomatic (symp-
tom free), improved, and no improvement. Also on follow-up
tear meniscus height was recorded and lacrimal syringing was
done. Tear meniscus height was recorded by using flouresce-
in dye and graded on slit lamp as high (>1 mm), moderate
(1 mm) and low (<1 mm).Syringing of the lacrimal passage
was done and results were noted as passage patent, partially
patent and complete block with regurgitation of fluid. Mann
Whitney test was used for comparing the results of the two
groups.Results
In our study there were 50 patients who underwent dacry-
ocystorhinostomy surgeries; 25 were in the Mitomycin C
group and the remaining 25 in the conventional group. Max-
imum number of patients belonged to the age group 31–
60 years (78%). There was no significant difference in age be-
tween the two groups (p > 0.05) (Table 1). There was a fe-
male preponderance in our study; 36 (72%) being female
and 14 (28%) being male (Table 1). However sex distribution
is comparable in both the groups.37 (74%) out of 50 cases
had right sided nasolacrimal duct obstruction (Table 2). On
presentation 86% (43/50) cases had watering with discharge
as the chief complaint. On ENT examination out of 50 cases
15 (30%) cases had mild deviated nasal septum, 7 (28%) cases
in the Mitomycin C group and 8 (30%) in the conventional
group (Table 2).
Intraoperative complications occurred in 10 cases. Injury
to nasal mucosa occurred in 5 (10%) cases, sac injury in 1
(2%), and severe bleeding in 4 (8%) patients, 2 each in both
groups (Table 3). Intraoperative complications in the two
groups were comparable. The immediate post operative
complications were epistaxis and wound infection. Epistaxis
occurred in 5 (10%) patients; 3 in the conventional group
and 2 in the Mitomycin C group. Wound infection was seen
in 2 patients in the conventional group (Table 4).
Symptomatically 24 (96%) cases in the Mitomycin C group
were asymptomatic with no symptoms where as 1 (4%) had
no improvement at the end of 6 months. In the conventional
group 20 (80%) cases were symptom free; whereas 5 (20%)
cases were symptomatic. There was no statistical significance
between the two groups (p = 0.085) (Table 5).
At the end of 6 months in the conventional group 20 (80%)
eyes had patent passage on lacrimal syringing, where as 1
(4%) eye had a partially patent passage; 4 (16%) eyes had
complete block and regurgitation of mucopurulent fluid. In
Mitomycin C group 24 (96%) eyes had patent passage on lac-
rimal syringing while only 1 (4%) eye had complete block with
regurgitation of mucopurulent fluid. However no statistical
significance was seen between the two groups (p = 0.088)
(Table 5).
On assessing tear meniscus height, 24 (96%) cases in the
Mitomycin C group had normal height at the end of
6 months, only 1 (4%) case had a high tear meniscus height.
Table 1. Age and Gender Distribution
Mitomycin C Conventional P value
n % n %
Age (years) <30 3 12.0 2 8.0 0.303 (NS)
30–39 6 24.0 4 16.0
40–49 7 28.0 7 28.0
50–59 6 24.0 9 36.0
P60 3 12 3 12.0
Mean ± SD 43 ± 12.6 (20.64) 47.3 ± 11.5 (27.64)
Gender Male 6 24 8 32.0 0.533 (NS)
Female 19 76 17 68.0
Table 2. Clinical Examination
MMC Conventional P value
n % n %
Laterality Right 18 72.0 19 76.0 0.750 (NS)
Left 7 28.0 6 24.0
History of watering Yes 2 8.0 2 8.0 1.000 (NS)
History of discharge Yes 22 88.0 21 84 0.687 (NS)
ENT Deviated Nasal septum Yes 7 28.0 8 32.0 0.760 (NS)
Tear meniscus height Moderate 21 84 19 76.0 0.484 (NS)
High 4 16 6 24.0
Lacrimal sac syringing CB + RTMF 25 100.0 25 100.0 1.000 (NS)
Clinical diagnosis CDC 25 100.0 25 100.0 1.000 (NS)
Table 3. Intraoperative Complications
MMC Conventional P value
n % n %
Sac mucosal damage 1 4.0 0 0.0 0.922 (NS)
Severe bleeding 2 8.0 2 8.0
Nasal mucosal damage 2 8.0 3 12.0
Normal 20 80.0 20 80.0
46 M. Qadir et al.In comparison 20 (80%) cases had a normal meniscus height
whereas 1 (4%) case and 4 (16%) cases had moderate and
high tear meniscus height, respectively. Again there was no
statistical difference between the two groups (p = 0.088)
(Table 5).Discussion
Chronic dacrocystitis is preferentially more common in
adults over middle life from 5th to 7th decade.3–6 In the pres-
ent study maximum number of patients (46 (78%)) belonged
to the middle aged group (31–60 years). In the study con-
ducted by B.J. Goswami et al7 overall age range was be-




Wound infection 0 0.0
Normal 22 88.0
Syringing day 1 (passage patent) 25 100.015–69 (average 38.2 years) in the other group. In the present
study age range in the conventional group was 27–64 years
(average 47.3 years) and age range in the Mitomycin C group
was 27–62 years (average 43.4 years). Thus this is comparable
with previous studies with no significant difference in age be-
tween the two groups.
In the present study 36 (72%) patients were female and 14
(28%) were male, thus showing female dominance. This is in
total agreement with all the previously done studies which
demonstrate female predilection of dacrocystitis with male:
female ratio 1:3.3,4 This may be attributed to the presence
of narrower lumen of bony lacrimal canal and lower nasolac-
rimal fossa in females.3,4,8
Contrary to previous studies, majority of the cases (37
(74%)) in our study had dacrocystitis on the right side. Dacro-
cystitis has been noted to occur more frequently on the left
side than right.8 Probably a larger sample would have shown
similar results as quoted in the literature. All the patients had
uncomplicated chronic dacrocystitis. 15 (30%) cases in our
study had mild deviated nasal septum where as failure was
seen in 4 (11.4%) cases out of 35 patients without deviated
nasal septum; this demonstrates that failure of surgery can-
not be attributed to mild deviated nasal septum. In our study
severe intraoperative bleeding was seen in 4 (8%) cases, 2
cases in each group, respectively, and was due to injury toConventional P value
n %
2 8.0 0.760 (NS)
2 8.0
21 84.0
25 100.0 1.000 (NS)
Table 5. Postoperative follow up.







Normal Moderate High Asymptomatic Improved No
improvement
1st Week MMC 0 (0.0%) 1 (4.0%) 24 (96.0%) 24 (96.0%) 1 (4%) 0 (0%) 24 (96%) 0 (0%) 1 (4%)
Conventional 0 (0%) 3 (12%) 22 (88%) 22 (88%) 3 (12%) 0 (0%) 22 (88%) 1 (4.0%) 2 (8%)
P value 0.303 (NS) 0.303 (NS) 0.312 (NS)
3rd Week MMC 0 (0.0%) 1 (4.0%) 24 (96.0%) 25 (100%) 0 (0%) 0 (0%) 24 (96%) 0 (0%) 1 (4%)
Conventional 0 (0.0%) 4 (16%) 21 (84%) 21 (84%) 4 (16%) 0 (0%) 21 (84%) 1 (4.0%) 3 (12%)
P value 0.162 (NS) 0.039 (NS) 0.168 (NS)
1 (4.0%)
6th Week MMC 1 (4.0%) 0 (0%) 24 (96%) 24 (96%) 0 (0%) 1 (4.0%) 24 (96%) 0 (0%) 1 (4.0%)
Conventional 1 (4.0%) 4 (16%) 20 (80%) 20 (80%) 3 (12%) 2 (8%) 20 (80%) 0 (0%) 5 (20%)
P value 0.099 (NS) 0.095 (NS) 0.085 (NS)
3rd Month MMC 1 (4.0%) 0 (0%) 24 (96%) 24 (96%) 0 (0%) 1 (4.0%) 24 (96%) 0 (0%) 1 (4.0%)
Conventional 3 (12%) 2 (8%) 20 (80%) 20 (80%) 2 (8%) 3 (12%) 20 (80%) 0 (0%) 5 (20%)
P value 0.092 (NS) 0.092 (NS) 0.085 (NS)
6th Month MMC 1 (4.0%) 0 (0%) 24 (96%) 24 (96%) 0 (0%) 1 (4.0%) 24 (96%) 0 (0%) 1 (4.0%)
Conventional 4 (16%) 1 (4.0%) 20 (80%) 20 (80%) 1 (4.0%) 4 (16%) 20 (80%) 0 (0%) 5 (20%)
P value 0.088 (NS) 0.088 (NS) 0.085 (NS)
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incising the nasal mucosa. The injured angular vessels were
clamped and ligated to stop further bleeding. Identification
and retraction of angular vessels with the help of retractors
can prevent injury to the angular vessels. Bleeding occurring
during punching of lacrimal bone was managed by mechani-
cal pressure from swabs soaked with botroclot solution. Na-
sal repacking with gauze moistened with 2% lignocaine
with adrenaline was also done to stop bleeding. Bleeding
from nasal mucosa was controlled in a similar manner.
Tarbet and Custer9 have reported post operative epistaxis
in 3.9% cases of external dacryocystorhinostomy. In our study
epistaxis was seen postoperatively in 5 (10%) cases, 3 in the
Mitomycin C group and 2 in the conventional group; this
was noticed after removal of nasal pack on the 1st post oper-
ative day. None of the cases required anterior nasal packing
and were managed conservatively on tablet ethamsylate 3
times a day for 3 days. 2 (4%) cases of post operative wound
infection were seen in the conventional group. One of these
cases also had severe intraoperative bleeding. It was man-
aged conservatively with systemic antibiotics, and topical anti-
biotics. Response to treatment was good. No case of wound
infection was seen in the Mitomycin C group. Goswami and
colleagues7 in their study have reported delayed wound heal-
ing in 2 patients and recurrent epistaxis in one patient as com-
plications due to Mitomycin C use. Shu Liao and colleagues1
have reported only one case of delayed wound healing due
to Mitomycin C use however no Mitomycin C induced compli-
cations such as severe nasal bleed, mucosal necrosis, wound
infection and delayed wound healing were seen in our study.
In our study there were 4 (16%) cases who had high tear
meniscus height (>1 mm)at the end of 6 months in the con-
ventional group. 1 (4%) eye had moderate tear meniscus
height (1 mm) and 20 eye samples (80%) had normal tear
meniscus height (<1 mm). In the Mitomycin C group 1 eye
(4%) had high tear meniscus height at the end of 6 months
and 24 eyes (96%) had normal tear meniscus height. The
objective finding of tear meniscus although does not show
statistical significance demonstrates the efficacy of Mitomy-
cin C application. Shu Liao et al1 in their study have reported
32 (72.7%) eyes having normal tear meniscus height, 7 (16%)having moderate tear meniscus height and 5 (11.3%) eyes
having high tear meniscus height in the conventional group.
In the Mitomycin C group out of 44 eyes in their study, 41
(93.1%) eyes had normal tear meniscus height, 1 eye (2.3%)
had moderate and 2 eyes (4.6%) had high tear meniscus
height. This is in total agreement with the present study dem-
onstrating the high efficacy of Mitomycin C.
At the end of 6 months, 20 (80%) cases in the conventional
group and 24 (96%) cases in the Mitomycin C group had pat-
ent passage on lacrimal syringing. Failed cases showed either
clear fluid regurgitation or mucopurulent regurgitation on
lacrimal sac syringing. In the study conducted by Seyhmus
Ari et al10 on lacrimal sac syringing 96% had patent passage
in the Mitomycin C group and 84% in the conventional group
had patent passage at the end of 1 year. Our results are also
comparable to the study conducted by Shu Liao et al1 where
88.4% of cases in the conventional group and 95.5% of cases
in the Mitomycin C group had patent passage on lacrimal sac
syringing. This indicates the efficacy of Mitomycin C in
increasing the patency rate of the lacrimal drainage system,
although the statistical difference is not significant.
All failed cases in both the groups were subjected to ENT
evaluation. All 6 patients showed narrowed osteum and soft
tissue scar and membrane across the ostium on anterior rhi-
noscopy. Medical management with nasal decongestants
and probing of lacrimal tract was done in these cases. Repeat
dacryocystorhinostomy was done in 3 cases in the conven-
tional group and one case in the Mitomycin C group, but res-
urgery was very difficult because of dense scarring.
Although the success rates did not reach statistical signif-
icance a distinctly higher success has been achieved in pa-
tients undergoing dacrocystorhinostomy with intraoperative
Mitomycin C cases compared to patients undergoing con-
ventional dacrocystorhinostomy. Thus it can be concluded
from our present study intraoperative use of Mitomycin C im-
proves the success rate of external dacrocystorhinostomy
and hence can be considered as a safe and effective modifi-
cation of conventional dacrocystorhinostomy. As our study
involved a small sample size and follow-up period of
6 months, studies involving larger sample size and a longer
follow-up period would be required for better evaluation of
48 M. Qadir et al.efficacy of intraoperative Mitomycin C during dacrocystorhi-
nostomy. Mitomycin C is likely to be more helpful in repeat
dacrocystorhinostomy but since this subset was excluded,
this study cannot comment on it.Conflict of interest
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